Annexin Pharmaceuticals AB (publ) (ANNX.ST)

SEK 0.43

(-1.61%)

Annual Income Statements

(In SEK)
Breakdown 2023 2022 2021 2020 2019 2018
Revenue - - - - - -
Cost of Revenue 193 Thousand 193 Thousand 192 Thousand 193 Thousand 193 Thousand 193 Thousand
Gross Profit -193 Thousand -193 Thousand -192 Thousand -193 Thousand -193 Thousand -193 Thousand
Operating Expenses 44.17 Million 40.65 Million 52.82 Million 44.62 Million 28.1 Million 28.36 Million
Selling, General and Administrative Expenses 8.01 Million 12.28 Million 10.69 Million 10.97 Million 7.52 Million 8.14 Million
Research and Development Expenses 36.02 Million 28.36 Million 42.13 Million 33.64 Million 21.38 Million 20.39 Million
Other Expenses 137 Thousand - - - -805 Thousand -173 Thousand
Cost and Expenses 44.17 Million 40.65 Million 52.82 Million 44.62 Million 28.1 Million 28.36 Million
Operating Income -44.17 Million -40.72 Million -51.23 Million -43.73 Million -28.32 Million -28.7 Million
Interest Expense - 2000.00 1.85 Million 503 Thousand 33 Thousand 147 Thousand
Income Tax Expense - -193 Thousand 909 Thousand 503 Thousand 33 Thousand -496.14 Thousand
Earnings before Tax -44.05 Million -40.72 Million -52.14 Million -44.24 Million -28.36 Million -28.84 Million
Net Income -44.05 Million -40.72 Million -53.05 Million -44.74 Million -28.39 Million -28.84 Million
Earnings Per Share Basic -0.26 -0.17 -0.39 -0.39 -0.57 -1.37
Earnings Per Share Diluted -0.26 -0.17 -0.39 -0.39 -0.57 -1.37
Weighted Average Shares Outstanding 167.1 Million 241.45 Million 135.42 Million 114.21 Million 49.55 Million 21.03 Million
Weighted Average Shares Outstanding (Diluted) 167.1 Million 241.45 Million 135.42 Million 114.21 Million 49.55 Million 21.03 Million
Gross Margin - - - - - -
EBIT Margin - - - - - -
Profit Margin - - - - - -
EBITDA -43.86 Million -40.53 Million -50.09 Million -43.54 Million -28.13 Million -28.5 Million
Earnings Before Tax Margin - - - - - -

Income Statement Charts